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Abstract
Background: Patients with biliary obstruction are at high risk to develop septic complications after endoscopic
retrograde cholangiography (ERC). We evaluated the benefits of local application of antimicrobial agents into ERC
contrast media in preventing post-ERC infectious complications in a high-risk study population.
Methods: Patients undergoing ERC at our tertiary referral center were retrospectively included. Addition of vancomycin,
gentamicin and fluconazol into ERC contrast media was evaluated in a case-control design. Outcomes comprised
infectious complications within 3 days after ERC.
Results: In total, 84 ERC cases were analyzed. Primarily indications for ERC were sclerosing cholangitis (75%)
and malignant stenosis (9.5%). Microbial testing of collected bile fluid in the treatment group was positive in
91.4%. Detected organisms were sensitive to the administered antimicrobials in 93%. The use of antimicrobials
in contrast media was associated with a significant decrease in post-ERC infectious complications compared
to non-use (14.3% vs. 33.3%; odds ratio [OR]: 0.33, 95% confidence interval [CI]: 0.114–0.978). After adjusting
for the variables acute cholangitis prior to ERC and incomplete biliary drainage, the beneficial effect of intraductal
antibiotic prophylaxis was even more evident (OR = 0.153; 95% CI: 0.039–0.598, p = 0.007). Patients profiting most
obviously from intraductal antimicrobials were those with secondary sclerosing cholangitis.
Conclusion: Local application of a combination of antibiotic and antimycotic agents to ERC contrast media efficiently
reduced post-ERC infectious events in patients with biliary obstruction. This is the first study that evaluates ERC-related
infectious complications in patients with secondary sclerosing cholangitis. Our first clinical results should now
be prospectively evaluated in a larger patient cohort to improve the safety of ERC, especially in patients with
secondary sclerosing cholangitis.
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Background
Infections such as cholangitis and sepsis are serious, al-
beit rare complications after endoscopic retrograde cho-
langioscopy (ERC). Post-ERC infections are reported to
occur in less than 5% of all interventions [1, 2]. High hy-
gienic standards for the intervention itself and thorough
disinfection and storage of endoscope and endoscopic
devices have essentially attributed to this low infectious
rate [3]. Procedural improvements such as endoscopic
decompression by biliary stents and immediate place-
ment of percutaneous biliary drainage if endoscopic
drainage is not possible, represent further strategies to
reduce the incidence of ERC-related infectious complica-
tions [4, 5]. This is an important issue, as failure to re-
store an adequate drainage after injection of contrast
media into obstructed bile tracts during ERC still repre-
sents the major risk factor for post-ERC infection [6, 7].
Obstruction of the bile duct system due to stones,
strictures and tumors has been demonstrated to be asso-
ciated with bacteriobilia [8]. Increasing intrabiliary pres-
sure (>25 mmHg) results in biliovenous reflux and
consecutively in bacteremia in case of already infected
bile [9, 10]. Injection of contrast media during ERC
raises the intraductal pressure, especially if a complete
endoscopic drainage is not achieved thereafter. Therefore,
patients with hilar tumors and sclerosing cholangitis for
whom complete biliary drainage is often impossible, are at
highest risk to develop post-ERC infections [11, 12].
Routine prophylactic use of systemic antibiotics was
shown to reduce ERC-related bacteremia [13]. However,
beneficial effects on preventing post-ERC cholangitis in
unselected patients could not be demonstrated [14–16].
A recent retrospective study analyzed the benefit of sys-
temic antibiotic prophylaxis in 11.484 patients undergo-
ing ERC over an 11-year period [17]. At baseline all
patients with biliary obstruction, immunosuppression
and the need of therapeutic intervention (95% of all pro-
cedures) received routinely systemic prophylactic anti-
biosis. Over time, the use of prophylactic antibiotics was
sequentially reduced. In the final phase, systemic anti-
biotic prophylaxis was restricted to patients for whom
endoscopic drainage was predicted to be incomplete and
to patients with immunosuppressive therapy (26% of all
procedures). Despite the limited use of systemic anti-
biotic prophylaxis, no significant difference in infectious
complications after ERC was observed. These data are in
line with the current recommendations of antibiotic
prophylaxis in gastrointestinal endoscopy [18, 19]. Sys-
temic antibiotic prophylaxis should be considered before
an ERC in those patients with known or suspected bil-
iary obstruction for whom complete endoscopic drainage
will presumably not be achieved. This concerns espe-
cially patients with hilar strictures and primary scleros-
ing cholangitis (PSC).
Of note, biliary excretion of systemically administered
antibiotic agents was shown to be low in case of biliary
obstruction or hepatic dysfunction [20]. Thus, antibiotic
bile concentrations may be far below the minimal inhibi-
tory concentration (MIC). Theoretically, local applica-
tion of antibiotics into the ERC contrast media should
result in high antibacterial concentration within the bile.
Thus, this regimen is supposed to be especially effective in
preventing ERC-related cholangiosepsis. Indeed, in vitro
studies have demonstrated that addition of gentamicin to
the ERC contrast media eliminated bacteriobilia [21]. In a
high-risk study population, the combination of intraven-
ous and intraductal antibiotic administration was shown
to efficiently prevent post-ERC infectious complications
[22]. Most recently, adding gentamicin to contrast media
had no significant effect on the incidence of post-ERC
cholangitis, however adequate drainage of biliary obstruc-
tion by stenting was obtained in all these patients [23].
Taking these rather heterogeneous and inconsistent
data into account, we aimed to evaluate whether local
application of antimicrobial agents into contrast media
will be beneficial to reduce post-ERC infectious compli-





This retrospective single-center study covers an 8-year-
period from January 2003 to December 2011. During
this time, 1353 patients with biliary obstruction under-
went ERC. Of these, 101 patients received antimicrobial
agents into the ERC contrast media. 59 patients with in-
complete follow up or with ERC within the preceding
70 days were excluded from this study. 13 patients
underwent ERC with similar indication twice within
5 years with and without intraductal antibiotics, respect-
ively. These were included as case- and control-ERCs
into our study. 29 patients with antibiotic application
into the contrast media during ERC were matched to 29
control patients without antibiotic administration in re-
spect to indication of ERC, age and sex. In summary,
our study encompasses 84 ERC cases with 42 cases re-
ceiving antibiotics into the ERC contrast media and 42
control cases without antibiotics.
Demographic data
Mean age of the predominantly male (71%) study popu-
lation was 52 +/- 16.2 years. All patients presented with
biliary obstruction. Malignant strictures (cholangiocellu-
lar carcinoma [n = 5], pancreatic cancer [n = 2], metasta-
sis [n = 1]) and sclerosing cholangitis (primary sclerosing
cholangitis [n = 20] and secondary sclerosing cholangitis
[n = 44]) were the most prevalent causes of biliary
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obstruction. Other etiologies of obstructive bile tract sys-
tem included choledocholithasis (n = 4), benign stenosis
after liver transplantation (n = 2), acute cholangitis due
to stent obstruction (n = 3) or benign stricture (n = 1)
and chronic cholangitis (n = 2). Thus, the study popula-
tion was mainly composed of high-risk patients regard-
ing infectious post-ERC adverse events.
Definition of ERC-related infectious complications
In case of absent non-/biliary infection by the time of ERC
(a) a rise in body temperature > 38 °C within 24 h after
ERC (in case of body temperature < 38 °C before ERC) or
(b) increase of white blood cell count and/or CRP over
upper normal limits in combination with elevation of
transaminases (Δ10 U/l) and bilirubin (Δ1.5 mg/dl) within
3 days after ERC were defined as infectious complication.
When non-/biliary infection was present by the time
of ERC, (c) a rise in body temperature > 38 °C within
24 h after ERC (incase of body temperature < 38 °C be-
fore ERC) or (d) increase of white blood cell count of
Δ2000/μl within 3 days after ERC or (e) increase of CRP
Δ50 mg/l within 3 days of ERC characterized infectious
complication.
Definition of successful ERC
ERC was categorized as successful when (a) biliary
drainage was restored and laboratory tests for alkaline
phosphatase, γ-glutamyltransferase and bilirubin as well
as transaminases decreased after ERC, (b) in case of
sclerosing cholangitis: laboratory tests for alkaline phos-
phatase, γ-glutamyltransferase and bilirubin as well as
transaminases decreased after ERC, even if complete biliary
decompression failed, and (c) in case of stent removal/re-
placement: laboratory tests for alkaline phosphatase, γ-
glutamyltransferase and bilirubin as well as transaminases
remained at least stable.
Statistical analysis
All statistical analyses were performed with SPSS Version
22 (SPSS Inc., Chicago, IL, USA). Descriptive data of pa-
tients are presented as mean values with the interquartile
range for continuous variables or percentage for categorial
variables. Pearsons’s chi-squared test was used to compare
categorial data. Factors influencing the risk of post-ERC
infectious complications were analyzed using binary logis-
tic regression models. Due to the low patient numbers, it
was predefined that only the two presumably most im-
portant risk factors for infectious complications, namely
presence of acute cholangitis at ERC, and incomplete
biliary drainage, would be included in the multivariate
logistic regression to calculate the effect of intraductal ad-
ministration of antimicrobial agents on post-ERC infec-
tious complications. Values of p <0.05 were considered to
be statistically significant.
Results
Patient demographics and clinical features
Eighty-four cases of biliary obstruction undergoing ERC
in our tertiary referral center were analyzed in this retro-
spective study to evaluate the benefit of antimicrobial
agents added to the contrast media on the rate of post-
ERC infectious complications. Therefore, 42 cases receiv-
ing antibiotics into ERC contrast media were matched to
42 controls without antibiotics for the parameters age, sex
and etiology of biliary obstruction. Patient characteristics
are shown in Table 1 for both groups.
In the treated group (n = 42) the following antimicro-
bial agents were administered to 50 ml contrast media
(Optiray 300 g/ml): gentamicin 80 mg (2 ml), vanco-
mycin 500 mg (5 ml) and fluconazole 40 mg (20 ml).
Most patients in the treated group received a combin-
ation of all antimicrobial agents (n = 29; 69% of treated
cases). Solely gentamicin was given in 7 cases (16.7%),
whereas a combination of both antibiotics was admin-
istered in 6 cases (14.3%). In addition, 51.3% (43/84)
of all patients received a systemic antibiotic treatment
within 28 days prior to and at ERC. Of note, there
was no statistical difference between the two study
groups regarding frequency of systemic antibiotic
treatment (24/42 patients in the treated group vs. 19/
42 in the control group, p = 0.28). Most frequently,
patients with secondary sclerosing cholangitis (SC)
[29 out of 44 SC-patients, 65.9%], with primary scler-
osing cholangitis (PSC) [6 out of 20 PSC-patients,
30%] and with choledocholithiasis [3 out of 4 pa-
tients, 75%] received systemic antibiotic treatment
prior to and at ERC. The main indication for anti-
biotic treatment was acute cholangitis.
Table 1 Clinical characteristics of the study population





Mean age 51.8 ± 16.4 52.4 ± 16.2 0.26
Male (n; %) 30 (71) 30 (71)
Etiology of biliary obstruction (n; %)
• Sclerosing cholangitis 32 (76) 32 (76)
• Malignant stricture 4 (10) 4 (10)
• Choledocholithiasis 2 (5) 2 (5)
• Benign stricture 1 (2) 1 (2)
• Cholangitis 3 (7) 3 (7)
Immunosuppressive
medication (n; %)
11 (26) 14 (33) 0.49
Hospitalization (d) 13.9 ± 21.1 13.3 ± 16.6 0.47
Cholangitis at ERC (n; %) 27 (64) 23 (55) 0.37
Non-biliary infection (n; %) 16 (38) 13 (31) 0.49
Patients were matched in respect to age, sex and indication for ERC
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Details on ERC data are shown in Table 2. There was
no statistical difference between the two groups regard-
ing the endoscopic procedures.
Microbial cultures of bile samples
Thirty-five bile samples (83.3% of the treated cases)
taken from patients receiving antimicrobial agents
into the contrast media were analyzed on microbial
colonization (Table 3). Only three bile cultures (8.6%)
were tested negative for bacterial and fungal species.
The most frequently isolated bacterial organisms in
the collected bile samples were Enterococcus spp.
found in 71.4% (25/35), E. coli in 25.7% (9/35), Klebsiella
spp. in 11.4% (4/35), Pseudomonas spp. in 11.4% (4/
35) and other gram-negative bacteria in 11.4% (4/35).
Candida spp. were isolated in 25.7% (9/35) of the bile
samples. Polymicrobial infection was detected in 54%
(19/35) of bile samples. The results of the antibio-
gram were not available for 7 bile cultures. In 3 bile
samples the isolated bacteria were resistant to the ad-
ministered intraductal antibiotics. All Candida species
were sensitive to fluconazole.
Antimicrobial agents in ERC contrast media reduced
ERC-related infectious complications
ERC-related infectious complications were observed in
23.8% of patients (20/84). While 33.3% (14/42) of
patients not subjected to antimicrobial agents into the
contrast media developed a post-ERC infectious compli-
cation, only 14.3% (6/42) patients receiving antibiotics
within the ERC contrast media presented with signs and
symptoms of infection (OR = 0.33, 95% CI 0.114–0.978;
p < 0.04; Fig. 1). Hence, the risk to develop an infectious
complication after ERC was 2.33-fold higher when ERC
was performed without administering antimicrobial
agents to the contrast media.
Among the 20 patients with post-ERC infectious com-
plications, frequency of systemic antibiotic treatment
was comparable in both study groups. In the treated
group, three out of the 6 patients (50%) with ERC-
related infectious complications received systemic anti-
biotic treatment. In the control group, eight out of the
14 patients (57%) with post-ERC infections were treated
with systemic antibiotics at time of ERC.
The main known factors that influence the rate of
post-ERC infectious complications are acute cholangitis
prior to ERC and the completeness of biliary drainage
[6]. At the time of ERC, 59.5% (50/84) cases of our study
population displayed acute cholangitis. Incidence of acute
cholangitis was similar in both study groups (p = 0.37).
Univariate logistic regression analysis revealed a positive
correlation between acute cholangitis prior to ERC and
the incidence of ERC-related infectious complications
(OR = 4.214; 95% CI: 1.034–17.173; p = 0.045). Incomplete
drainage is considered as the main reason for administer-
ing prophylactic systemic antibiotic treatment in ERC.
The ERC success rate of complete drainage achieved in
our study was comparatively low (41.7%). Success rate was
similar in both study groups (p = 0.07). In contrast to pre-
vious studies, we could not detect a significant benefit of
successful ERC for prevention of infectious adverse events
(OR = 0.368; 95% CI: 0.101–1.337; p = 0.13). After adjust-
ment for the confounders “cholangitis” and “ERC success
rate”, the beneficial effect of antimicrobial agents applied
to contrast media for the prevention of ERC-related infec-
tious complications was even more evident (OR = 0.153;
95% CI: 0.039–0.598; p = 0.007).
Secondary sclerosing cholangitis was the most eligible
biliary disorder profiting from intraductal antimicrobial
prophylaxis
Secondary sclerosing cholangitis (SC) was the predomin-
ant etiology of biliary obstruction in our study popula-
tion (52.4% of all cases). SC represents a progressive
disease characterized by fibrosis and destruction of the
biliary tract system leading to biliary cirrhosis. SC in
critically ill patients (SC-CIP), known to be associated






Papillotomy 16 11 0.24
Stone removal 6 3 0.29
Necrosis removal 3 1 0.3
Dilatation 12 5 0.06
Lavage 4 3 0.69
Nasobiliary drain 5 3 0.46
Stenting 0.84
• Stent insertion 4 4
• Stent exchange 3 2
• Stent removal 2 3
Table 3 Bile cultures of bile samples from patients receiving
antimicrobial agents into ERC contrast media
Cultures positive for n (%)
Enterococcus spp. 25 (71.4%)
E. coli 9 (25.7)
Klebsiella spp. 4 (11.4)
Pseudomonas spp. 4 (11.4)
Candida spp. 9 (25.7)
Other gram-negative 4 (11.4)
Polymicrobial 19 (54.0)
Note, that the sum of percentages may be greater than 100 because of
polymicrobial infections
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with a particularly rapid and aggressive progression to
liver cirrhosis [24], was the most common cause of SC
in our study population (32/44, 72.7%). Other causes of
SC were ischemic cholangiopathy after liver transplant-
ation (3/44, 6.8%), immunologic (4/44; 9.1%), toxic (2/
44, 4.5%), infectious (1/44, 2.3%) and unknown (2/44,
4.5%). Subgroup analysis revealed that 65% (13/20) of
the patients with post-ERC infection suffered from SC.
When adding antimicrobial agents to ERC contrast
media in patients with SC, we noted a significant de-
crease in infectious complications after ERC (2/22, 9%
vs. 11/22, 50% in SC patients not given antibiotics into
the contrast media; p = 0.03; Fig. 2). Furthermore, 77%
(10/13) of the SC-patients with ERC-related infectious
complications received a systemic antibiotic treatment
before and at time of ERC. Moreover, 80% (8/10) of
these SC-patients had no local antibiotic prophylaxis
and developed post-ERC infectious complications des-
pite a systemic antibiotic treatment.
Discussion
The presented study demonstrates several important
findings that may give cause to modify the current practice
of antibiotic prophylaxis to prevent ERC-related infectious
complications. These include: (1) addition of antimicrobial
agents into the ERC contrast media significantly reduces
the incidence of post-ERC infection in patients with biliary
obstruction; (2) combination of different antibiotics and an-
tifungal regiments might be even more effective; (3) the
benefit of local application of antimicrobials into obstructed
bile ducts is most obvious if cholangitis is already present
before ERC; (4) secondary sclerosing cholangitis represents
the most eligible biliary disorder which takes particular
profit from locally administered antimicrobials during ERC.
The routine administration of systemic antibiotic prophy-
laxis to all patients undergoing ERC has been left in favor
of a selective use only in those patients with suspected or
known biliary obstruction for whom complete endoscopic
drainage will presumably not be achieved. This concerns
Fig. 1 ERC-related infectious complications. Patients with antibiotic prophylaxis within the contrast media developed post-ERC infectious complications
significantly less frequent than patients not receiving antimicrobial agents (14.3% versus 33.3%, p < 0.04)
Fig. 2 Subgroup analysis of patients with sclerosing cholangitis (SC). Addition of antimicrobial agents to ERC contrast media in patients with SC
resulted in a significant decrease in infectious complications after ERC (9% with antibiotics vs. 50% without antibiotics, p = 0.03)
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particularly patients with hilar strictures and PSC [19]. Pa-
tients with post-transplant biliary strictures undergoing
ERC represent other feasible candidates for systemic anti-
biotic prophylaxis [21]. Since systemically administered
antibiotics poorly penetrate into the bile in case of biliary
obstruction [20, 25, 26], a theoretical benefit of injecting
antimicrobial agents directly into the bile tracts during ERC
is assumable. Several studies have investigated the effect of
antibiotics applied in contrast media on preventing post-
ERC cholangitis with conflicting results. In vitro studies
have proven that aminoglycosides retain their antibacterial
properties when mixed to ERC contrast media. Thus, the
aminoglycosides tobramycin and gentamicin efficiently
eliminated common biliary bacteria such as E. coli, Klebsi-
ella pneumonia, Proteus vulgaris and Pseudomonas aerugi-
nosa [21, 27]. In line with these findings, we observed a
significantly reduced post-ERC infection rate in patients
with biliary obstruction when antimicrobial agents were
added into the ERC media. Patients not receiving intraduc-
tal antibiotics into ERC contrast media exhibited a 2.33-fold
increased risk to develop post-ERC cholangitis.
In contrast to our results, 3 prior prospective
randomized-controlled studies could not demonstrate
a beneficial effect on the rate of post-ERC infectious com-
plications by adding antibiotics into ERC contrast media
[23, 28, 29]. To explain these discrepancies, one has to
take into account that only an aminoglycoside was used in
the three studies, and that the analyzed study population
strongly differed in matters of endoscopic procedures and
subtype of biliary disorders. In the two randomized con-
trolled studies published in 1980 and 1986 [28, 29], 51% of
the study population underwent solely diagnostic ERC
and did not exhibit any biliary disorder, whereas in our
study all patients suffered from mainly severe obstructive
biliary disease. In the most recent study [23] 114 pa-
tients with non-calculous biliary obstruction were en-
rolled, 57 of them receiving gentamicin 10 mg into
ERC contrast media. In addition, all of them received
a peri-interventional systemic antibiosis. Biliary ob-
struction was mainly caused by malignant strictures
(79% of cases vs. 9.5% in our study), whereas in our
study sclerosing cholangitis (75%) was the most
prevalent cause. In contrast to our study, all patients
underwent endoscopic biliary stenting (vs. 9.5% in our
study). Biliary obstruction was relieved resulting in an
adequate drainage in all patients, whereas in our
study only in 49.3% of therapeutic ERC adequate
drainage was achieved. In the mentioned study, no
significant difference in the incidence of post-ERC
cholangitis in each group with and without gentami-
cin added to contrast media (8.8% each) was detected.
In contrast, in our study the incidence of post-ERC
infection was significantly lower when adding anti-
microbial agents into the ERC contrast media (14.3%
vs. 33% in the control group; p = 0.045). The absolute
risk reduction was 19% when adding antimicrobial
agents into the ERC contrast media. We suggest that
patients with secondary sclerosing cholangitis, who
presented 52.4% of our study population, are particu-
larly prone to post-ERC infectious complications. Pre-
sumably, the ERC-related infectious risk in these
patients is even more pronounced than in patients
with malignant strictures. Thus, 65% (13/20) of the
patients with post-ERC infection suffered from SC in
our study. SC is a chronic cholestatic biliary disease
characterized by PSC-like biliary lesions apparent on
ERC, namely multifocal biliary strictures with inter-
posed normal or dilated bile ducts [24]. The most fre-
quent cause (72.7%) of SC in our study population
was SC in critically ill patients (SC-CIP). SC-CIP is
an emerging disease entity with unfavorable outcome,
mostly observed in patients who have survived life-
threatening illnesses and who received aggressive treat-
ment on intensive-care units. The median survival of
patients with SC-CIP who are not liver-transplanted was
reported to be only 13 months [30]. ERC reveals severe
bile-duct damage with extensive biliary casts and multiple
irregular strictures. Recurrent episodes of bacterial chol-
angitis are typically observed in patients with SC [31, 32].
In 68.2% of our patients with SC, bile fluid was tested
positive for bacteria before ERC with no statistical differ-
ence between the two study groups. However, infectious
complication rate after ERC was significantly higher in
patients with SC not given antibiotics into the contrast
media (50% vs. 9%; p = 0.03). In these SC-patients, ERC-
related infectious complications were observed even
despite a systemic antibiotic treatment. Regarding the
other subgroups of the study population, addition of anti-
biotics to the contrast media seemed to have no effect on
the post-ERC infectious rate, although patient numbers
are too small for valid statistical analysis.
Patients presenting with fever or elevated leucocytes
prior to ERC were excluded from all previous studies
that evaluated the benefit of intraductal antibiotics on
post-ERC complications [23, 28, 29]. In contrast, 59.5%
of our study population suffered already at the time of ERC
from acute cholangitis (defined as bacterial colonization of
the biliary system and elevated leucocytes > 12 000/μl/
CRP > 5 mg/l). Acute cholangitis at the time of ERC was
present in both, the case- and control group without statis-
tical difference. Injection of ERC contrast media into
obstructed and infected bile tracts will most likely result in
bacteremia [8]. This will particularly be the case when
complete biliary drainage is not achieved by ERC. On the
other hand, addition of antimicrobial agents to the ERC
contrast media should reduce biliary bacterial growth and
decrease the risk of bacteremia. Indeed, acute cholangitis,
present at the time of ERC, was calculated as a risk factor
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for developing post-ERC infectious complications in our
study. Hence, the risk of infectious complications after
ERC was 2.72-fold increased when acute cholangitis was
present compared to patients without cholangitis. The ab-
solute risk reduction was 29,3% in patients with cholangitis
when adding antibiotics to contrast media. In line with our
data, Motte et al. identified leukocytosis and prior cholan-
gitis as significant risk factors for septicemia following
endoscopic biliary stenting of biliary obstruction [6].
Most patients in our study received a combination of
antimicrobial agents into the ERC contrast media. Only
16.6% received solely gentamicin, as used in the previous
studies [23, 29]. The most frequently isolated organism
in bile samples taken from patients given intraductal
antibiosis were gram-positive with Enterococcus spp.
found in 71.4%. Gram-negative organisms found in the
collected bile samples were E. coli in 25.7%, Klebsiella
spp. in 11.4% and Pseudomonas spp. in 11.4%. Of note,
only in 10.7% of positive bile cultures, all detected bac-
terial strains were sensitive to gentamicin. Combination
of gentamicin with vancomycin increased the response
rate to 89.3%. These data question the effectiveness of
adding solely gentamicin into ERC contrast media for
prevention of post-ERC infectious complications. In-
stead, the choice of the administered antibiotic regi-
ments should be based on the sensitivity of the isolated
bacteria and the local pattern of antibiotic resistance.
Noteworthy, we found Candida species in 25.7% of the
fungal cultures of taken bile samples. All Candida spe-
cies were sensitive to fluconazole. Candida spp. were
shown to be predominantly detected in bile fluids of pa-
tients with primary and secondary sclerosing cholangitis,
immunosuppressive therapy, after placement of plastic
biliary stents, and after liver transplantation [33–36].
Our data on fungal bile cultures are in line with these
findings, as our study population comprises all the men-
tioned entities above. In conclusion, collection of bile
fluid during ERC for microbiological analysis should be
considered in all patients with a high risk for post-ERC
infectious complications. When adding antimicrobial
agents into ERC contrast media, we recommend a com-
bination of antibiotic and antimycotic agents instead of
mono-therapy suggesting a more potent effect on pre-
venting post-ERC infectious complications.
The main limitations of our study are the retrospective
study design and the rather small number of patients.
Moreover, the combination of antimicrobial agents added
to the contrast media was not standardized in a uniform
protocol, but was recommended to the respective investi-
gator. This explains the number of patients receiving
solely gentamicin, or an antibiotic regiment without anti-
mycotic agents. Despite these limitations, our data are of
particular interest for the clinical practice of antibiotic
prophylaxis in ERC. This is the first study that evaluates
ERC-related infectious complications in patients with SC.
Pre-procedural cholangitis and incomplete endoscopic
drainage due to multifocal biliary strictures are common
findings in patients with SC, defining them as a high risk-
population for post-ERC infectious complications. Injec-
tion of ERC contrast media might increase the intraductal
pressure and incomplete drainage of already infected bile
might then facilitate bacteremia in SC. A benefit of locally
applied antibiotic agents is therefore highly assumable.
Our preliminary data should now be prospectively evalu-
ated in a larger patient cohort to improve the safety of
ERC, especially in patients with SC.
Conclusion
Based on our study results, we recommend the local
application of antimicrobial agents into ERC contrast
media especially in patients with SC in addition to the
established systemic antibiotic prophylaxis.
Abbrevations
CI: Confidence interval; ERC: Endoscopic retrograde cholangiography;
OR: Odds ratio; PSC: Primary sclerosing cholangitis; SC: Secondary sclerosing
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